Spruce Biosciences to Participate in the Jefferies Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the Jefferies Global Healthcare Conference on June 5, 2024, at 5:00 p.m. ET.

Interested parties can access the live webcast here. An archived copy of the webcast will be available on the events section of the company’s investor relations website for approximately 90 days.

About Spruce Biosciences

Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal, once-daily therapy for patients suffering from classic congenital adrenal hyperplasia (CAH) and other endocrine disorders. To learn more, visit www.sprucebio.com and follow us on X, LinkedIn, Facebook, and YouTube.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240522135392/en/

Media Contact
Katie Beach Oltsik
Inizio Evoke Comms
(937) 232-4889
[email protected]
[email protected]

Investors
Samir Gharib
President and CFO
Spruce Biosciences, Inc.
[email protected]

Source: Spruce Biosciences, Inc.

You May Also Be Interested In

• Catalyst by Zoho Solves The Shortfalls of Moving from Coding to Production With an Agent-Ready, Full-Stack Cloud and Built-In Governance
• Houlihan Lokey Continues to Expand European Financial Sponsors Coverage Team With Senior Hire in France
• PetSuper to Showcase Its Evolution Toward AI-Powered Pet Health Management at IFA 2026